Category: Forbes

Billionaire Los Angeles Times Owner Patrick Soon-Shiong Accused Of ‘Catch-And-Kill’ Scheme—With A Cancer Drug

Sorrento Therapeutics alleges in a complaint that billionaire Soon-Shiong kept a cancer drug from making it to market to eliminate a competitor to a drug he invented.

How To Pay Family Members For Providing Eldercare

40 million family members are providing care for an aging parent. This article outlines a procedure for these caregivers to get paid legally for their efforts.

As More Rite Aids Close, Walgreens May Accelerate ‘Small Store’ Development

Walgreens is testing a “small store format” while amid a “comprehensive review” to address underperforming retail locations.

Big Data Big News: Largest Health Data Org on Planet Promises “Actionable” Info Release

The largest health data steward “on the planet,” the Department of Health and Human Services, plans to make its data releases actionable for entrepreneurs and patients. The clinical and economic impact of this connected health information could be enor…

Cigna’s Express Scripts PBM To Cap Insulin Costs Amid Drug Price Scrutiny

Cigna and Express Scripts are rolling out a new program to cap out-of-pocket costs for insulin at $25 per 30-day prescriptions.

Cigna’s Express Scripts PBM To Cap Insulin Costs Amid Drug Price Scrutiny

Cigna and Express Scripts are rolling out a new program to cap out-of-pocket costs for insulin at $25 per 30-day prescriptions.

How Virtual Reality Can Help Those With Autism

The VR industry has a huge role in shifting how we use technology to help support those on the autistic spectrum to connect, communicate and navigate. Plus, it can help those without the condition learn more about it.

Healthcare Startups Raised $1.5 Billion In March

For the second month in a row venture capital fundraising among healthcare startups is down almost 50% year-over-year, but 2019’s first quarter total is the second-highest in the past decade, according to an analysis conducted for Forbes by Pitchbook.

Walgreens Shares Are Still Worth Shorting Even After Today’s Huge Decline

Walgreens management has lost credibility with analysts, and that–for any company–is a situation in which owning its stock can be an expensive mistake.

Walgreens: ‘Our Execution Is Lacking’

Walgreens said it will increase an annual cost cutting strategy to “in excess of $1.5 billion” by 2022 from $1 billion.